Prime Medicine, Inc. Common Stock Cash Flow-to-Debt Ratio
Prime Medicine, Inc. Common Stock cash flow-to-debt ratio. Prime Medicine, Inc. Common Stock (PRME) has a Cash Flow-to-Debt Ratio of -0.20x as of June 2026, meaning its operating cash flow of $-41.05 Million could theoretically repay 0% of its total liabilities ($209.23 Million) in one year. Check PRME cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Prime Medicine, Inc. Common Stock (2019–2025)
Cash flow-to-debt ratio of Prime Medicine, Inc. Common Stock from 2019 to 2025. Historical debt coverage capacity for Prime Medicine, Inc. Common Stock across 7 annual periods. Check PRME cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Prime Medicine, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2019–2025)
Prime Medicine, Inc. Common Stock cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Prime Medicine, Inc. Common Stock. For the full cash flow conversion analysis, see PRME cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.73x | $-162.56 Million | $221.87 Million | ▲ +13.9% |
| 2024 | -0.85x | $-122.86 Million | $144.36 Million | ▲ +68.7% |
| 2023 | -2.72x | $-165.41 Million | $60.78 Million | ▲ +9.1% |
| 2022 | -2.99x | $-131.83 Million | $44.04 Million | ▼ -447.1% |
| 2021 | -0.55x | $-34.08 Million | $62.30 Million | ▼ -110.3% |
| 2020 | -0.26x | $-5.54 Million | $21.31 Million | ▼ -42.5% |
| 2019 | -0.18x | $-1.33 Million | $7.31 Million | — |